Novartis PAH drug shows efficacy in Phase III trial
The 24-week randomized placebo-controlled, double-blind, multi-center Impres trial involving 202 patients is intended to evaluate the efficacy and safety of oral QTI571 as an add-on therapy in the
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.